Malaria research deal seeks to make up for industry's retreat
Article Abstract:
The UK Department for International Development and the world Health Organization (WHO) are pledging funds for research into the discovery and development of new drugs against malaria. The New Medicines for Malaria Venture (MMV) will funded by public sector and philanthropic bodies, but operated as an industrial R&D programme. Proponents include pharmaceutical bodies such as Glaxo-Wellcome, the International Federation of Pharmaceutical Manufacturers Association and Hoffman-La Roche.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Can industry be wooed back into the act?
Article Abstract:
The pharmaceutical industry is unlikely to commit more funding to malaria research until there is sufficient economic development in continents such as Africa and Asia. Most drugs companies have stopped supporting vaccine and drug development programmes because they are expensive and unlikely to yield high profits. However, experts at scientific institutes such as the World Health Organisation are striving to attract help from industry.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Antarctica research essential for continued influence, says panel. Congress cool on research funding proposals
- Abstracts: Panel calls for overhaul of AIDS research. NIH strives to keep resource sharing alive. NIH's way of setting priorities endorsed
- Abstracts: Parasite clones in the wild. Bottoms up for the oceans. Case studies of extinction
- Abstracts: Time to put malaria control on the global agenda. Research 'essential' for control strategy. Vaccines: a roller-coaster of hopes
- Abstracts: Global agencies hold the financial key. The spirit of Dakar: a call for action on malaria